Ancillary risk information and pharmacogenetic tests: social and policy implications
Open Access
- 8 May 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in The Pharmacogenomics Journal
- Vol. 8 (2), 85-89
- https://doi.org/10.1038/sj.tpj.6500457
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Mechanisms of Disease: β-adrenergic receptors—alterations in signal transduction and pharmacogenomics in heart failureNature Clinical Practice Cardiovascular Medicine, 2005
- Large Meta-Analysis Establishes the ACE Insertion-Deletion Polymorphism as a Marker of Alzheimer's DiseaseAmerican Journal of Epidemiology, 2005
- Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancerInternational Journal of Cancer, 2005
- Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin TreatmentCirculation, 2005
- Glutathione S-transferase M1 status and gastric cancer risk: a meta-analysisCancer Letters, 2005
- BiDil: Race Medicine Or Race Marketing?Health Affairs, 2005
- Effects of dopamine D2 receptor (DRD2) and transporter (SLC6A3) polymorphisms on smoking cue-induced cigarette craving among African-American smokersMolecular Psychiatry, 2004
- GSTM1, GSTT1 and GSTP1 polymorphisms, environmental tobacco smoke exposure and risk of lung cancer among never smokers: a population-based studyCarcinogenesis: Integrative Cancer Research, 2004
- Pharmacogenetics: ethical problems and solutionsNature Reviews Genetics, 2004
- Stress-induced cigarette craving: effects of the DRD2 TaqI RFLP and SLC6A3 VNTR polymorphismsThe Pharmacogenomics Journal, 2004